Hepatocellular carcinoma

Hepatocellular carcinoma
Other names	Hepatoma
Hepatocellular carcinoma in an individual who was hepatitis C positive. Autopsy specimen.
Specialty	Oncology

Hepatocellular carcinoma (HCC^[1]) is the most common type of primary liver cancer in adults and is currently the most common cause of death in people with cirrhosis.^[2] HCC is the third leading cause of cancer-related deaths worldwide.^[3]

HCC most commonly occurs in those with chronic liver disease especially those with cirrhosis or fibrosis, which occur in the setting of chronic liver injury and inflammation. HCC is rare in those without chronic liver disease. Chronic liver diseases which greatly increase the risk of HCC include hepatitis infection such as (hepatitis B, C or D), non-alcoholic steatohepatitis (NASH), alcoholic liver disease, or exposure to toxins such as aflatoxin, or pyrrolizidine alkaloids.^{[4][5]: 870–873} Certain diseases, such as hemochromatosis and alpha 1-antitrypsin deficiency, markedly increase the risk of developing HCC. The five-year survival in those with HCC is 18%.^[6]

As with any cancer, the treatment and prognosis of HCC varies depending on tumor histology, size, how far the cancer has spread, and overall health of the person.

The vast majority of HCC cases and the lowest survival rates after treatment occur in Asia and sub-Saharan Africa, in countries where hepatitis B infection is endemic and many are infected from birth. The incidence of HCC in the United States and other higher income countries is increasing due to an increase in hepatitis C virus infections. The incidence of HCC due to NASH has also risen sharply in the past 20 years, with NASH being the fastest growing cause of HCC.^[6][7] This is thought to be due to an increased prevalence of NASH, as well as its risk factors of diabetes and obesity, in higher income countries.^[8] It is more than three times as common in males as in females, for unknown reasons.^{[5]: 870–873}